ANIK Financial Facts

Diluted weighted average common shares outstanding: 14.36M
Interest income (expense), net: -39.56K
See Full Income Statement

Cash and cash equivalents: 50.97M
Less: accumulated depreciation: -17.09M
See Full Balance Sheet

Earnings History for Anika Therapeutics Inc. (ANIK)

  |   Expand Research on ANIK
Next EPS Date 5/1/13 *Est. EPS Growth Rate +47.6% *Last Qtr.
Average EPS % Beat Rate +17.8% Revenue Growth Rate +22.8% *Last Qtr.
Average % Move 1-Wk after EPS +12.7%    
Date  Qtr EPS Cons. Surprise Revs Cons. Estimize EPS/Revs Gd. % Since Details
3/9/11 Q410 $0.10N/A N/A $14.2MN/A N/A / N/A N/A +62.9% Details
5/4/11 Q111 $0.02N/A N/A $11.7MN/A N/A / N/A N/A +75% Details
8/4/11 Q211 $0.17N/A N/A $16.1M$13.7M N/A / N/A N/A +140.8% Details
2/29/12 Q411 $0.21N/A N/A $18.4M$14.7M N/A / N/A N/A 0% Details
11/2/11 Q311 $0.22$0.11 +$0.11$18.5M$15.1M N/A / N/A N/A +138.4% Details
10/30/12 Q312 $0.11$0.17 -$0.06$14.8M$16.83M N/A / N/A N/A +18.5% Details
5/3/12 Q112 $0.14$0.17 -$0.03$14.4M$18.2M N/A / N/A N/A -13.4% Details
2/27/13 Q412 $0.31$0.25 +$0.06$22.6M$21.59M N/A / N/A N/A +34.5% Details